Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Oncology Practice

• Publication date

  2012-01-17

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1200/JOP.2011.000287PMID 22942813PMCID PMC3396807
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers

  2013cited by this paper
• Beta-blockers, trimethoprim-sulfamethoxazole, and the risk of hyperkalemia requiring hospitalization in the elderly: a nested case-control study.

  2010cited by this paper
• Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

  2009cited by this paper
• Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study

  2009cited by this paper
• Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

  2009cited by this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cited by this paper
• Creating Demand for Prescription Drugs: A Content Analysis of Television Direct-to-Consumer Advertising

  2007cited by this paper
• Erythropoietin, the FDA, and oncology.

  2007cited by this paper
• Outpatient gatifloxacin therapy and dysglycemia in older adults.

  2006cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2005cited by this paper
• Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

  2005cited by this paper
• Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.

  2004cited by this paper
• Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.

  2003cited by this paper
• Metformin and thiazolidinedione use in Medicare patients with heart failure.

  2003cited by this paper
• Risks of blood transfusion

  2003cited by this paper
• Frequency of inappropriate metformin prescriptions.

  2002cited by this paper
• When are medication side effects due to the nocebo phenomenon

  2002cited by this paper
• Contraindicated use of cisapride: impact of food and drug administration regulatory action.

  2000cited by this paper
• Chemotherapy-induced anemia in adults: incidence and treatment.

  1999cited by this paper
• The Frequency of Red Cell Transfusion for Anemia in Patients Receiving Chemotherapy A Retrospective Cohort Study

  1993cited by this paper
• [Risks of blood transfusion].

  1981cited by this paper

• Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach

  2022cites this paper
• Barriers and facilitators to the uptake of new medicines into clinical practice: a systematic review

  2021cites this paper
• Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial

  2021cites this paper
• Do drug‐related safety warnings have the expected impact on drug therapy? A systematic review

  2020cites this paper
• End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia

  2020cites this paper
• Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.

  2017cites this paper
• Infective Endocarditis Hospitalizations and Antibiotic Prophylaxis Rates Before and After the 2007 American Heart Association Guidelines Revision.

  2017cites this paper
• The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men

  2014cites this paper
• Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.

  2014cites this paper
• Drivers of change in cancer care.

  2014cites this paper